7060 POSTER Assessment of Angiogenic Factors and Hematopoietic Stem Cells and Their Relevance as Prognostic Factors for Overall Survival (OS) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients (pts): a Prospective Study

2011 ◽  
Vol 47 ◽  
pp. S503
Author(s):  
D. Hellev ◽  
R. Elaidi ◽  
J. Gachet ◽  
E. Kempf ◽  
M. Brizard ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Stem Cells ◽  
Overall Survival ◽  
Prognostic Factors ◽  
Prospective Study ◽  
Hematopoietic Stem Cells ◽  
Castration Resistant Prostate Cancer ◽  
Hematopoietic Stem ◽  
Castration Resistant ◽  
A Prospective Study

Bone Loss in Long-Term Survivors after Transplantation of Hematopoietic Stem Cells: A Prospective Study

2000 ◽  
Vol 11 (4) ◽  
pp. 344-353 ◽  
Author(s):  
C. Schulte ◽  
D. W. Beelen ◽  
U. W. Schaefer ◽  
K. Mann
Keyword(s):  
Stem Cells ◽  
Bone Loss ◽  
Prospective Study ◽  
Hematopoietic Stem Cells ◽  
Hematopoietic Stem ◽  
A Prospective Study ◽  
Long Term Survivors

scholarly journals Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features

2009 ◽  
Vol 20 (4) ◽  
pp. 703-708 ◽  
Author(s):  
Y. Loriot ◽  
C. Massard ◽  
M. Gross-Goupil ◽  
M. Di Palma ◽  
B. Escudier ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prospective Study ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Pretreated Patients ◽  
A Prospective Study

Abstract 2694: The impact of curcumin plus docetaxel on neuroendocrine features, or not, in castration-resistant prostate cancer: A prospective study

2012 ◽  
Author(s):  
Eloïse Planchat ◽  
Jean-Christophe Eymard ◽  
Hervé Curé ◽  
Xavier Durando ◽  
Chantal Barthomeuf ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prospective Study ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
A Prospective Study ◽  
The Impact

Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study

Urology ◽  
2017 ◽  
Vol 108 ◽  
pp. 135-141 ◽  
Author(s):  
Helle D. Zacho ◽  
Michael Gade ◽  
Jesper C. Mortensen ◽  
Henrik Bertelsen ◽  
Søren K. Boldsen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prospective Study ◽  
Bone Scan ◽  
Independent Predictor ◽  
Newly Diagnosed ◽  
Castration Resistant Prostate Cancer ◽  
Bone Scan Index ◽  
Castration Resistant ◽  
A Prospective Study

Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer

2015 ◽  
Vol 68 (1) ◽  
pp. 42-50 ◽  
Author(s):  
Karim Fizazi ◽  
Christophe Massard ◽  
Matthew Smith ◽  
Michael Rader ◽  
Janet Brown ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Prognostic Factors ◽  
Bone Metastases ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

Prognostic factors for overall survival in patients with metastatic castration-resistant prostate cancer: Secondary analysis.

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. e597-e597 ◽  
Author(s):  
Andrea Carolina Anampa-Guzman ◽  
Oliver Sulca-Huamani ◽  
Rushmely Perez-Mendez ◽  
Gloria Mendoza-Soto ◽  
Pamela Contreras Chavez ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Multivariate Analysis ◽  
Prognostic Factors ◽  
Performance Status ◽  
Secondary Analysis ◽  
Rank Test ◽  
Poor Performance Status ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

e597 Background: The standard treatment for metastatic castration-resistant prostate cancer (MCRPC) is Docetaxel (DTX); however, it has serious adverse effects. It is necessary to know the prognostic factors for overall survival (OS) of patients with MCRPC treated with DTX. The aim of this study was to determine the prognostic factors for OS in patients with MCRPC treated with DTX. Methods: This study is a secondary analysis of the control arms of the clinical trials NTC00273338, NCT00519285 and NCT00988208. 1600 patients aged 18 years or older with MCPRC that received DTX and prednisone were included. Survival curves were estimated by Kaplan-Meier and comparison was done by log-rank test. Multivariate analysis for overall survival (OS) was performed with the Cox proportional hazard regression model. Results: The median OS time was 14.64 months. The 1-yr-OS and 2-yrs-OS were 86.2% and 28.6%, respectively. Patients with an ECOG score greater than 0 lived significantly less than the rest of patients (p = 0.00). The patients with an alkaline phosphate level (ALP) > 200 had significantly lower OS (p = 0.00). In the multivariate analysis, the factors that influenced OS were ECOG, ALP, HB, LDH and number of metastases. Conclusions: Poor performance status, high alkaline phosphatase level, low hemoglobin level, high LDH and more than 2 metastases were the main prognostic factors in patients with metastatic castration resistant prostate cancer. [Table: see text]

A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study

2012 ◽  
Vol 13 (11) ◽  
pp. 1105-1113 ◽  
Author(s):  
Robert W Ross ◽  
Matthew D Galsky ◽  
Howard I Scher ◽  
Jay Magidson ◽  
Karl Wassmann ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prospective Study ◽  
Whole Blood ◽  
Prognostic Model ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
A Prospective Study ◽  
Rna Transcript
Sign in / Sign up

Export Citation Format

Share Document